Deracoxib-d₃  (Synonyms: 地拉考昔-d₃; SC 046-d₃; SC 46-d₃; SC 59046-d₃)

Deracoxib-d₃ (SC 046-d₃; SC 59046-d₃) is the deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.

1. 该化合物可作为示踪剂。
2. 该化合物可作为 NMR、GC-MS 或 LC-MS 分析中的内标品，用于定量分析。

氢、碳和其他元素的稳定重同位素已被整合到药物分子中，主要用作药物研发过程中定量分析的示踪剂。氘化因其可能影响药物的药代动力学和代谢特征而备受关注。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

400.39

C₁₇H₁₁D₃F₃N₃O₃S

2012598-48-8

169590-41-4

地拉考昔-d₃

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.  [Content Brief]

  [2]. Royals, S.R., et al., Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res, 2005. 66(11): p. 1961-7.  [Content Brief]

  [3]. Ustun Alkan, F., et al., The effects of piroxicam and deracoxib on canine mammary tumour cell line. ScientificWorldJournal, 2012. 2012: p. 976740.  [Content Brief]

  [4]. Bienhoff, S.E., et al., Efficacy and safety of deracoxib for control of postoperative pain and inflammation associated with soft tissue surgery in dogs. Vet Surg, 2012. 41(3): p. 336-44.  [Content Brief]

  [5]. McMillan, S.K., et al., Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc, 2011. 239(8): p. 1084-9.  [Content Brief]